CARGO Therapeutics, Inc. (CRGX) announced a definitive merger agreement with Concentra Biosciences, LLC.
Under the terms, Concentra Biosciences will acquire CARGO Therapeutics for $4.379 in cash per share of its common stock.
Following a strategic review process involving CARGO, Inc. management and advisors, Concentra will begin a tender offer by July 21, 2025, to purchase all outstanding shares.
The merger transaction involving CARGO Therapeutics, Inc. (CRGX) is expected to close in August 2025.